Regeneron (REGN) Says EYLEA Clinically Equivalent to Lucentis Following VIEW 1, 2 Phase 3s

Go back to Regeneron (REGN) Says EYLEA Clinically Equivalent to Lucentis Following VIEW 1, 2 Phase 3s

Leerink Swann Raises Price Target on Regeneron (REGN) to $182

October 22, 2012 2:26 PM EDT

Leerink Swann reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $182.00 (from $150.00).

MEDACorp conducted a survey of 50 U.S.ophthalmologists and based on the results analyst at Leerink Swan created a revenue model that... More